1 252

Cited 4 times in

A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome

Authors
 Junsoo Park  ;  Ji-Youn Chun  ;  Jang Hwan Kim  ;  Si-yeol Cheon  ;  Miho Song  ;  Myung-Soo Choo  ;  Kyu-Sung Lee  ;  Seung-June Oh  ;  Joon Chul Kim  ;  Jong Bo Choi  ;  Ju Tae Seo  ;  Sung Yong Cho 
Citation
 INTERNATIONAL UROLOGY AND NEPHROLOGY, Vol.47(2) : 235-242, 2015 
Journal Title
 INTERNATIONAL UROLOGY AND NEPHROLOGY 
ISSN
 0301-1623 
Issue Date
2015
MeSH
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Medication Adherence* ; Middle Aged ; Muscarinic Antagonists/adverse effects* ; Prospective Studies ; Quinuclidines/adverse effects* ; Severity of Illness Index ; Solifenacin Succinate ; Tetrahydroisoquinolines/adverse effects* ; Treatment Outcome ; Urinary Bladder, Overactive/drug therapy* ; Xerostomia/chemically induced* ; Young Adult
Keywords
Antimuscarinic ; Dry mouth ; Overactive bladder ; Solifenacin ; Urinary urgency ; Xerostomia
Abstract
PURPOSE: Dry mouth is among the most common side effects of antimuscarinic therapy. This study evaluated the drug-related change in dry mouth after the solifenacin treatment and the impact of dry mouth on the drug efficacy against overactive bladder syndrome (OAB). MATERIALS AND METHODS: OAB patients (n = 331) were enrolled in a prospective, multicenter, 8-week observational study of solifenacin treatment. Participants were >20 years of age and presented with OAB symptoms for ≥3 months, a total overactive bladder symptom score (OABSS) of ≥3, and an urgency score of ≥2. Primary endpoints were changes in dry mouth according to baseline dry mouth status using Xerostomia Inventory (XI) and the effect of dry mouth to the drug efficacy according to improvements in the OABSS. RESULTS AND CONCLUSIONS: Three hundred and thirty-three patients were initially screened for the study, with 331 actually enrolled. One hundred and ninety-four patients completed the study. Mean total XI scores increased by 2.8 points in the entire patient population, with larger increases for patients stratified into the non-dry mouth group (NDG) versus the dry mouth group (DG) (4.0 vs. 1.9, p = 0.015) at study baseline. Mean total OABSSs decreased by 3.2 points, with no significant differences between the NDG and the DG (-3.4 vs. -3.0 points, p = 0.578). The dry mouth aggravated in 71 patients (29.2 %) (NDG 30.1 % and DG 27.1 %), but only 10/331 individuals (3.0 %) stopped medication due to xerostomia. Dry mouth progressed in approximately 30 % of the OAB patients, regardless of its presence before solifenacin treatment. However, OAB symptoms were well relieved by solifenacin, and the adverse influence of dry mouth on drug persistence was low.
Full Text
http://link.springer.com/article/10.1007%2Fs11255-014-0892-x
DOI
10.1007/s11255-014-0892-x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jang Hwan(김장환) ORCID logo https://orcid.org/0000-0002-9056-7072
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/139849
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse